• ACTG Adds New Agent to ACTIV-2 Trial Investigating Early COVID-19 Treatments

    January 5, 2021 Alexis Sexton Spotlight

    The AIDS Clinical Trials Group (ACTG), the largest global HIV research   network, today announced the addition of a new agent to the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial. This phase 2 study, which is being led by the ACTG, will evaluate the combination of the two monoclonal antibodies BRII-196 and BRII-198 to treat early COVID-19. ACTIV-2 includes both phase 2 and phase 3 evaluations of multiple promising investigational agents for treating early, symptomatic COVID-19 in a single trial. For information about enrolling in the trial, please visit the study website.

    For more information click here.

  • NIH Re-Funds ACTG for the Next Seven Years

    December 9, 2020 Alexis Sexton Spotlight

    The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, has been re-funded for the next seven years by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and collaborating NIH Institutes. The group is led by Judith Currier, M.D., M.Sc, Professor of Medicine at the University of California, Los Angeles (UCLA) and Joseph Eron M.D., Professor of Medicine, University of North Carolina. The Operations Center is based at UCLA.

    Read more about this here.

  • Ned Sacktor

    December 1, 2020 Alexis Sexton Spotlight

    We learned the sad news on Monday that our colleague Dr. Ned Sacktor passed away on November 11, 2020 from pancreatic cancer. Ned was a neurologist and investigator at the Johns Hopkins University ACTG CRS for 20 years. During that time, he contributed to carrying out the ACTG’s neurology agenda as a long-standing member and former chair of the neurology committee and as a protocol leader or member on several neurology protocols. We extend our heart-felt condolences to his wife and daughters and to his colleagues from around the globe.

  • 2020 ACTG Awards

    November 24, 2020 Alexis Sexton Spotlight

    On November 16, 2020, the ACTG virtually presented the 2020 ACTG Awards. This year we have two new awards in honor of ACTG investigators and leaders who recently passed away. The following recipients have exemplified each award they received. Congratulations to all who were nominated and those who were selected! View the full virtual presentation HERE!

    To see the full list of awardees click here.

  • ACTG Presents Data Showing Minimal Monitoring Approach to Hepatitis C Treatment is Safe and Successful at AASLD’s 2020 Liver Meeting

    November 16, 2020 Alexis Sexton Spotlight

    The AIDS Clinical Trials Group (ACTG), the world’s largest and longest established HIV research network, presented today The “Keep it Simple and Safe” Approach to HCV Treatment: Primary Outcomes from the ACTG A5360 (MINMON) Study at AASLD’s virtual 2020 Liver Meeting. The study found that in a diverse, global patient population, a minimal monitoring (MINMON) approach to hepatitis C treatment was safe and achieved comparable sustained virologic response (SVR) to current standard of care. To read more click here.

  • In Memory of Timothy Ray Brown

    October 2, 2020 Alexis Sexton Spotlight

    With great sorrow, we share the news that Timothy Ray Brown passed on September 29, 2020. Timothy, who was previously known as the “Berlin Patient,” was the first person cured of HIV when he received bone marrow and stem cell transplants to treat his leukemia. The return of that cancer caused his death. To read more about Timothy please click here. To read the NY Times article on him click here.

  • ACTG REPRIEVE Chosen for ViiV Grant

    Congratulations to ACTG REPRIEVE, study A5332, for receiving a ViiV Global HIV and COVID-19 Emergency Response Fund grant! ViiV included REPRIEVE as one of 109 grantees out of over 400 grant applications.

  • An Update on A5395

    ACTG recently announced that it has stopped enrolling A5395, our clinical trial evaluating whether hydroxychloroquine and azithromycin can prevent hospitalization and death from COVID-19. This action was taken when it was determined that the rate of participant enrollment was insufficient for the trial to meet its objectives in a timely manner. No safety concerns were associated with the trial. ACTG remains highly involved in efforts to address COVID-19, having been asked to lead a Master Adaptive protocol under the Accelerating COVID-19 Therapeutic Interventions and Vaccine (ACTIV) Operation Warp Speed. This trial (ACTG 5401 or ACTIV-2) will evaluate multiple monoclonal antibodies and other small molecules for outpatient COVID treatment. The trial is set to open at the end of July.”

  • A Message from Leadership

    The ACTG leadership has watched with sadness and horror the recent racially motivated violent events, including the deaths of George Floyd by the police in Minneapolis, Ahmaud Arbery when out for a jog in South Georgia, and Breonna Taylor in her own home by police in Louisville, Kentucky. These devastating events are taking place in the context of the COVID-19 pandemic and subsequent economic downfall, both of which have disproportionately affected racial/ethnic minorities in the United States. The ACTG mourns these brutal deaths and recognizes the structural racism in the United States that has paved the way for these unjust murders and facilitated the disproportionate impact of COVID-19 on black and brown communities. We understand and empathize with the anger and frustration that is being felt and expressed across our nation about these senseless deaths and the injustice they represent. The ACTG and the HIV/AIDS community are committed to social justice and eliminating these disparities. Now is the time for us to all stand together and do our part to support efforts to dismantle structural racism, injustice, and brutality in the United States.

  • Larry Kramer

    The ACTG is deeply saddened by the passing of AIDS activist and playwright, Larry Kramer. To read more about his life and legacy, please see the New York Times article here.